SEC Form 4 · accession 0001179110-15-013872
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc D Kozin
Director
Period of report
Oct 5, 2015
Accepted (ET)
Oct 6, 2015 · 7:36 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 5, 2015 | P | 4,800 | $10.79 | A | 20,553 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.16 to $10.95, inclusive. The Reporting Person undertakes to provide OvaScience, Inc., any security holder of OvaScience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges sent forth in this footnote.